T Türsz

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al. · Journal of Clinical Oncology · 1999 · 565 citations

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Armando Santoro, T Türsz, Henning T. Mouridsen et al. · Journal of Clinical Oncology · 1995 · 526 citations

European Code Against Cancer and scientific justification: third version (2003)

Peter Boyle, Philippe Autier, Harry Bartelink et al. · Annals of Oncology · 2003 · 307 citations · Full text

Oncology, Cancer Epidemiology, Scientific Justification +9

Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

Axel Le Cesne, Ian Judson, D. Crowther et al. · Journal of Clinical Oncology · 2000 · 255 citations

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience

Antonio Llombart‐Cussac, Xavier Pivot, G Contesso et al. · British Journal of Cancer · 1998 · 157 citations · Full text

Surgical Oncology, Oncology, Adjuvant Chemotherapy +3